Subsequent Event

6 Months Ended

Jun. 30, 2021

Subsequent Events [Abstract]

Subsequent Event

13. Subsequent Event

In July 2021, we entered into agreements for additional clinical trial services for MarzAA and for our screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $3.2 million and $6.5 million, respectively. We can terminate these agreements at our discretion and upon termination will be responsible to pay for those services incurred prior to termination plus reasonable wind-down expenses.